The challenges of precision testing in bladder cancer: PD-L1 biomarker testing offers hope

30th May 2019
Bladder cancer is in an advanced stage by the time it is detected in approximately a quarter of patients at presentation. The initial symptoms of this disease (e.g. blood in the urine) often go unnoticed or are mistaken for other conditions such as a bladder infection. As with any cancer, the

Biomarker testing in melanoma: the many challenges of BRAF mutational status

7th May 2019
Malignant melanoma is the deadliest form of skin cancer. Fast-growing, melanoma is best beaten with an early and accurate diagnosis followed by the right treatment tailored to the patient based on the identification of a specific biomarker. Biomarkers can predict therapeutic response to treatment.

Why is asking for testing so important and so necessary?

4th February 2019
The Precision Medicine Connective is on a quest to help improve the diagnostic testing part of the patient journey. An important way to do this is by empowering patients to ask to be tested in ways that are relevant to them.   There are many problems that need addressing to improve diagnostic

Real Time Oncology Review (RTOR) – implications for launch and commercialization

23rd August 2018
The FDA intends to make the development and review of cancer drugs more efficient under the Real Time Oncology Review (RTOR) pilot program. Under this supplemental applications pilot, launched last year, evaluation of clinical data begins as soon as clinical data becomes available and results are

Innovation in Liquid Biopsy

22nd August 2018
The term “liquid biopsy” is defined by the College of American Pathologists (CAP) as assays that analyze proteins, DNA, or cancer cells that circulate in the blood. There is growing interest in the less invasive, less complicated liquid biopsy as an alternative option to traditional biopsies in

Trends in FLT3 testing

7th August 2018
The FMS-like tyrosine kinase 3 gene (FLT3) marker is present in 25-30% of all AML patients and indicates a poorer prognosis.  The testing landscape is evolving and FLT3 diagnostic testing is now used in efficacy-based patient stratification, safety-based patient stratification and ongoing

Spark and laboratory data

25th July 2018
At Diaceutics we are using a number of tools to leverage our data and to generate actionable insights.  We mine data to forecast market trends and to understand the changing biomarker landscape.  We are able to understand the use of new biomarker targets over time, review the dissemination of new

Precision Medicine (PM) and Artificial Intelligence (AI) algorithms – risk of bias in treatment

26th June 2018
Precision medicine is more impactful when we build a story through use of a complete and meaningful dataset. Many publications discuss the idea that precision medicine relies on smart technology and this is true. At Diaceutics we believe that smart technology needs to be paired with the right

CMS decision on NGS coverage is a big step forward for patients and laboratories

20th April 2018
By Jeff Schreier, Senior Director, Marketing and Robert Feeney, Marketing Director, Global Lab Relations, Diaceutics.  A hurdle has just been cleared for patients and the laboratories who serve them. On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National

Diaceutics, Intel and Lenovo advance patient care using AI and workstations powered by Intel® Xeon® Scalable processors

5th March 2018
Collaboration will help to organize and categorize patient testing data using artificial intelligence It is a revolutionary method which could help to identify new patient subsets The aim is to further improve the diagnosis and treatment of patients Since it was established, Diaceutics has focused

It’s a boy! Now where’s that genetic testing kit? 

28th February 2018
In a big step forward for early diagnostic use, US company Sema4 has begun offering a newborn genetic screening kit that analyses 166 genes for 193 disorders and 38 common pediatric diseases. Sema4 is a “health information company founded on the idea that more information, deeper

Could Crohn’s disease treatment become more precise?

19th February 2018
Crohn’s disease is an inflammatory condition that affects the gastrointestinal tract and can cause symptoms including abdominal pain, diarrhoea, bleeding, joint pain, mouth sores, fatigue and weight loss. The cause is unknown but bacteria and the immune system are implicated and there is
Load more